ExeVir
Public Health & Prevention · Infectious Disease Therapeutics
Overview
The growing world population and climate change give rise to increasing incidences and rapidly spreading infectious diseases.
Official records
Funding and backers
Backers
2
Fund+, V-Bio Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Registers and programsofficial lists and records that name the company
| Legal entity | ADDRESS Exevir Bio BV | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
T cell Based Immunotherapies for Cancer and Chronic Infectious Diseases.
Antibiotics once saved us—now it’s our turn. pRxcision® is the first AI-powered infectious disease platform delivering real-time decision…
Background monitoring for infectious disease, installed at your site. Untap turns wastewater into earlier, decision-ready warning for…
Paratek Pharmaceuticals is committed to developing and delivering innovative treatments for serious infectious diseases. Learn about our…
SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and…
Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Fund+Via a fund
V-Bio VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Report
ExeVir Announces Michael Garrett as New Chief Executive Officer
Company developing antibody therapeutics against emerging viral threatsMichel The post ExeVir Announces Michael Garrett as New Chief Executive Officer appeared first on ExeVir.
Read more
Report
ExeVir Announces Michael Garrett as New Chief Executive Officer
Company developing antibody therapeutics against emerging viral threatsGHENT, Belgium, Nov. 18, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing heavy chain-only antibodies targeting highly conserved epitopes for broad protection against
Read more
Report
Poster ID Week 2024
Poster presented by Florence Herschke at ID Week 2024, October 16-19, 2024, Los Angeles, USA The post Poster ID Week 2024 appeared first on ExeVir.
Read more
Report
Empowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013m data at ID Week 2024
media439244
Read more
Report
Empowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013m data at ID Week 2024
The post Empowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013m data at ID Week 2024 appeared first on ExeVir.
Read more
Report
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1
Photo by Önder Örtel on Unsplash The post ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1 appeared first on ExeVir.
Read more
Report
Join us at the Asia Dengue Summit 2024!
Connect with Florence Herschke, PhD, our head of preclinical development, and Tessa Van Royen, one of our research scientists, next week at the 7th Asia Dengue Summit in Kuala Lumpur. The post Join us at the Asia Dengue Summit 2024! appeared first on ExeV
Read more
Report
Poster ESCMID Global 2024 Conference
Poster presented by CSO Viki Bockstal at ESCMID Global, 27-30 April 2024 in Barcelona, Spain The post Poster ESCMID Global 2024 Conference appeared first on ExeVir.
Read more
Report
Member spotlight: ExeVir uses llama-derived antibodies to protect the vulnerable
MEDVIA article featuring ExeVir - Based on the interview with CSO, Viki Bockstal. By Amy LeBlanc. Images: Winter the llama Tim Coppens The post Member spotlight: ExeVir uses llama-derived antibodies to protect the vulnerable appeared first on ExeVir.
Read more
Report
Show more news